CD274 and neoplasm: In addition, we identified a TIL signature in pre-treatment tumor samples characterized by a dormant phenotype (i.e., high CD3+/low GZB/low Ki-67) that is associated with survival benefit to immune checkpoint blockers independent from the tumor mutational load and PD-L1 expression.